Advertisement
AXON or BEAM or SEER
Which Stock Would AI Choose? Axon Enterprise, Inc. (AXON) vs. Beam Therapeutics Inc. (BEAM) vs. Seer, Inc. (SEER) Stock Comparison
Key Takeaways
- AXON boasts robust revenue growth forecasts of 27-30% for 2026, driven by software and AI innovations, despite a recent 19% price pullback.
- BEAM benefits from positive gene-editing trial data and a new financing facility, supporting YTD gains of about 11% amid biotech volatility.
- SEER, a proteomics specialist, trades at low valuations with recent acquisition interest at $2.35 per share, but remains range-bound.
- AXON's $32B market cap dwarfs peers, reflecting established public safety dominance versus biotech risks in BEAM and SEER.
- All three show YTD gains around 10-29%, but AXON leads in scale and backlog stability.
Introduction
This stock comparison examines AXON, BEAM, and SEER amid evolving market dynamics in technology and biotech sectors. Investors seeking exposure to innovative growth areas—public safety tech, precision gene editing, and proteomics—may find value in analyzing their relative performance, momentum, and risk profiles. With recent earnings beats, clinical updates, and acquisition buzz, this analysis highlights key contrasts in business models and market positioning for informed trading decisions in a volatile environment.
AXON Overview and Recent Performance
Axon Enterprise, Inc. (AXON) develops public safety technologies, including TASER conducted energy devices, body cameras, and cloud-based evidence management software. In recent market activity, the stock has traded around $402, within a 52-week range of $339 to $886, reflecting YTD gains of 29% but a pullback of about 19% in recent weeks. Strong Q4 results showed 40% software revenue growth and a $14B backlog, fueled by AI tools like Draft One and a new 911 platform. Sentiment remains positive on 27-30% 2026 growth outlook, though elevated valuations (trailing P/E near 263) and competition temper enthusiasm.
BEAM Overview and Recent Performance
Beam Therapeutics Inc. (BEAM) focuses on precision genetic medicines via base editing technology, targeting diseases like sickle cell and alpha-1 antitrypsin deficiency. Shares hover near $31, in a 52-week range of $15 to $36, with YTD returns of 11% and recent upticks from clinical progress. Positive Phase 1/2 data for Ristoglogene autogetemcel and a $500M financing facility boosted sentiment in recent weeks, alongside Q4 revenue of $114M. However, negative EPS (-$0.81 TTM) underscores biotech risks, with performance tied to trial milestones and partnerships like Pfizer.
SEER Overview and Recent Performance
Seer, Inc. (SEER) provides proteomics tools like the Proteograph suite for deep proteome analysis in research. The stock trades around $2, in a tight 52-week range of $1.65 to $2.41, delivering modest YTD gains of 11% with flat annual performance. Recent weeks saw interest from an improved acquisition proposal at $2.35 per share, amid Q4 revenue of $4.2M and installed base growth via the Strategic Instrument Placement Program. Persistent losses (EPS -$1.28 TTM) and small $115M market cap highlight execution challenges in a competitive life sciences market.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top AI-powered trading bots, curated from over 351 total bots that trade thousands of tickers across stocks, ETFs, and crypto. Only the most suitable for current conditions—based on real-time performance in volatile markets—earn a spot among the 25 featured, with annualized returns ranging from 24% to 163%, win rates of 51% to 88%, and profit factors up to 11.7. Styles vary from short-term AI/ML signals (5-60 minutes) to swing trading with risk management like TP/SL corridors (e.g., 3% take-profit/2% stop-loss). These bots adapt to themes like semiconductors, volatility, and ETFs, often outperforming the S&P 500. Explore them for automated strategies tailored to today's market.
Head-to-Head Comparison
AXON’s hardware-software model in public safety contrasts with BEAM and SEER’s R&D-heavy biotech approaches, offering steadier recurring revenue via subscriptions versus milestone-driven catalysts. Growth drivers favor AXON’s international expansion and AI backlog over biotechs’ clinical risks. Recent momentum shows BEAM’s upside on data beats, while SEER lags in scale. Risks include AXON’s high valuation sensitivity and biotechs’ binary trial outcomes. Sector exposure pits defense-tech stability against biotech volatility, with AXON less sentiment-swayed.
Tickeron AI Verdict
Tickeron’s AI tools currently lean toward AXON for superior trend consistency, massive backlog, and projected growth amid relative stability, positioning it ahead of BEAM’s promising but volatile catalysts and SEER’s takeover speculation. This reflects observable momentum and lower downside risk in recent positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileBEAM’s FA Score has 1 green FA rating(s), and SEER’s FA Score reflects 1 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- BEAM’s FA Score: 1 green, 4 red.
- SEER’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while BEAM’s TA Score has 6 bullish TA indicator(s), and SEER’s TA Score reflects 6 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 4 bearish.
- BEAM’s TA Score: 6 bullish, 4 bearish.
- SEER’s TA Score: 6 bullish, 4 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а +3.43% price change this week, while BEAM (@Biotechnology) price change was +9.27% , and SEER (@Biotechnology) price fluctuated -1.61% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -1.28%. For the same industry, the average monthly price growth was +0.12%, and the average quarterly price growth was +44.60%.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.81%. For the same industry, the average monthly price growth was +2.53%, and the average quarterly price growth was +10.42%.
Reported Earning Dates
AXON is expected to report earnings on Aug 11, 2026.
BEAM is expected to report earnings on Aug 11, 2026.
SEER is expected to report earnings on May 13, 2026.
Industries' Descriptions
@Aerospace & Defense (-1.28% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (-2.81% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | BEAM | SEER | |
| Capitalization | 31.7B | 3.25B | 101M |
| EBITDA | 320M | -349.25M | -71.89M |
| Gain YTD | -30.685 | 13.925 | 0.000 |
| P/E Ratio | 158.73 | N/A | N/A |
| Revenue | 2.98B | 164M | 16.1M |
| Total Cash | 737M | 1.21B | 186M |
| Total Debt | 1.83B | 251M | 23.7M |
AXON | BEAM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 31 Undervalued | |
PROFIT vs RISK RATING 1..100 | 72 | 100 | |
SMR RATING 1..100 | 80 | 91 | |
PRICE GROWTH RATING 1..100 | 62 | 39 | |
P/E GROWTH RATING 1..100 | 56 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BEAM's Valuation (31) in the null industry is somewhat better than the same rating for AXON (83) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (72) in the Biotechnology industry is in the same range as BEAM (100) in the null industry. This means that AXON’s stock grew similarly to BEAM’s over the last 12 months.
AXON's SMR Rating (80) in the Biotechnology industry is in the same range as BEAM (91) in the null industry. This means that AXON’s stock grew similarly to BEAM’s over the last 12 months.
BEAM's Price Growth Rating (39) in the null industry is in the same range as AXON (62) in the Biotechnology industry. This means that BEAM’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for BEAM (100) in the null industry. This means that AXON’s stock grew somewhat faster than BEAM’s over the last 12 months.
| AXON | BEAM | SEER | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 1 day ago 81% | 1 day ago 74% |
| Stochastic ODDS (%) | 1 day ago 63% | 1 day ago 90% | 1 day ago 68% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 78% | 1 day ago 87% |
| MACD ODDS (%) | 1 day ago 76% | 1 day ago 81% | 1 day ago 77% |
| TrendWeek ODDS (%) | 1 day ago 76% | 1 day ago 80% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 73% | 1 day ago 77% | 1 day ago 72% |
| Advances ODDS (%) | 7 days ago 74% | 13 days ago 76% | 13 days ago 75% |
| Declines ODDS (%) | 1 day ago 69% | 1 day ago 84% | 3 days ago 84% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 89% | 1 day ago 79% |
| Aroon ODDS (%) | 1 day ago 74% | 1 day ago 67% | 1 day ago 85% |
Advertisement
AXON and
Correlation & Price change
A.I.dvisor indicates that over the last year, AXON has been loosely correlated with TECH. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if AXON jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To AXON | 1D Price Change % | ||
|---|---|---|---|---|
| AXON | 100% | -0.18% | ||
| TECH - AXON | 61% Loosely correlated | +0.02% | ||
| VCYT - AXON | 58% Loosely correlated | -0.38% | ||
| BEAM - AXON | 57% Loosely correlated | -0.54% | ||
| SEER - AXON | 56% Loosely correlated | N/A | ||
| ADPT - AXON | 56% Loosely correlated | +0.66% | ||
More | ||||
BEAM and
Correlation & Price change
A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To BEAM | 1D Price Change % | ||
|---|---|---|---|---|
| BEAM | 100% | -0.54% | ||
| CRSP - BEAM | 70% Closely correlated | -2.18% | ||
| EDIT - BEAM | 59% Loosely correlated | -3.92% | ||
| NTLA - BEAM | 58% Loosely correlated | -2.98% | ||
| RXRX - BEAM | 57% Loosely correlated | -3.68% | ||
| AXON - BEAM | 57% Loosely correlated | -0.18% | ||
More | ||||